We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Transasia Bio-Medicals Acquires Calbiotech Group

By LabMedica International staff writers
Posted on 01 May 2017
Print article
Image: The Calbiotech team (Photo courtesy of Calbiotech Group).
Image: The Calbiotech team (Photo courtesy of Calbiotech Group).
Transasia Bio-Medicals Ltd., an in-vitro diagnostic company, has acquired immunoassay developer and manufacturer Calbiotech Group of Companies through its subsidiary Erba Mannheim.

The Transasia- Erba Group offers a comprehensive portfolio in different specialties including clinical chemistry, immunology, hematology, hemostasis, critical care, electrophoresis, urinalysis, diabetes monitoring, autoimmune & infectious disease monitoring, molecular diagnostics and microbiology. Calbiotech is a worldwide leader in immunoassay development and manufacturing and was the first company to introduce immunoassay kits in the US to detect antibodies against Zika virus in human blood. The acquisition of Calbiotech has strengthened the Transasia-Erba Group’s foray into ELISA and CLIA assays for human and animal research, including specific assays for autoimmune disorders, cancer and infectious diseases.

“Calbiotech Inc. and Dr. Noori Barka have developed an excellent range of immunoassay products that will complement our growing range of diagnostic products. Globally, the immunology segment of the IVD industry is valued at around USD 15 billion,” said Mr. Suresh Vazirani, Chairman & Managing Director, Transasia-Erba Group. “Calbiotech’s expertise in immunoassay will allow us to strengthen our position in this high growth market and integrate their strong R&D program to further enhance the product development strategy of the Transasia- Erba Group.”

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The QIAstat-Dx Analyzer 2.0 with remote test results access enhances collaboration across the healthcare system (Photo courtesy of QIAGEN)

Upgraded Syndromic Testing Analyzer Enables Remote Test Results Access

QIAGEN (Venlo, the Netherlands) has released the QIAstat-Dx Analyzer 2.0, including the Software 1.6 upgrade. This represents a significant advancement from the initial QIAstat-Dx Analyzer 1.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The RedDrop One blood collection device has received 510(k) clearance from the U.S. FDA for prescription use (Photo courtesy of RedDrop Dx)

Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy

The discomfort associated with traditional blood draws leads to a significant issue: approximately 30% of diagnostic tests prescribed by physicians are never completed by patients. This avoidance is often... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.